Hemab Therapeutics Holdings, Inc. stock analysis
Hemab Therapeutics Holdings, Inc. (COAG) Stock Price & Analysis
COAG Stock Chart & Stats
- Day’s Range
- $37.58 - $40.61
- 52-Week Range
- $23.00 - $55.42
- Previous Close
- $39.06
- Volume
- N/A
- Average Volume (3M)
- 477.85K
- Market Cap
- $1.83B
- Enterprise Value
- $1.01B
- Total Cash (Recent Filing)
- $430.24M
- Total Debt (Recent Filing)
- $965.00K
- Price to Earnings (P/E)
- ―
- Beta
- -2.08
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Hemab Therapeutics Holdings, Inc. News
Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating
In a report released yesterday, Richard Law CFA from Goldman Sachs maintained a Buy rating on Hemab Therapeutics Holdings, Inc., with a price target of $46.00. Richard Law CFA has
Hemab Therapeutics: Advancing Pipeline, Regulatory Momentum, and Solid Cash Runway Support Buy Rating with Unchanged $40 Price Target
Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Hemab Therapeutics Holdings, Inc.. The associated price target remains the same with $40.00. Emily Bodnar has given his
COAG FAQ
What was Hemab Therapeutics Holdings, Inc.’s price range in the past 12 months?
What is Hemab Therapeutics Holdings, Inc.’s market cap?
When is Hemab Therapeutics Holdings, Inc.’s upcoming earnings report date?
How were Hemab Therapeutics Holdings, Inc.’s earnings last quarter?
Is Hemab Therapeutics Holdings, Inc. overvalued?
Does Hemab Therapeutics Holdings, Inc. pay dividends?
What is Hemab Therapeutics Holdings, Inc.’s EPS estimate?
How many shares outstanding does Hemab Therapeutics Holdings, Inc. have?
What happened to Hemab Therapeutics Holdings, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Hemab Therapeutics Holdings, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Hemab Therapeutics Holdings, Inc. Stock Smart Score
Company Description
Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Benny Sorensen
- Employees
- 59
- Website
- www.hemab.com
- Address
- 101 Main Street, Cambridge, MA, 02142, US
Hemab Therapeutics Holdings, Inc. (COAG) Earnings & Revenues
COAG Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, highlighted by initiation of Hemab's first pivotal Phase III trial, encouraging Phase II Glanzmann data, proof-of-mechanism and early bleeding observations for HMB-002, progress across all three programs, and a cash runway expected into 2029. The main negatives were higher operating expenses and net losses, thromboembolic events in higher-exposure cohorts, limited early clinical datasets, the FDA's recommendation to consider randomization for SOLARA, and the early development stage of HMB-003. Highlights significantly outweighed the lowlights.
View all COAG earnings summariesCOAG Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 8 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 3 | 0 | 7 |








